The aim of this study was to provide an overview of the literature available on dynamic contrast-enhanced computed tomography (DCE-CT) as a tool to evaluate treatment response in patients with lung cancer. This systematic review was compiled according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Only original research articles concerning treatment response in patients with lung cancer assessed with DCE-CT were included. To assess the validity of each study we implemented Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). The initial search yielded 651 publications, and 16 articles were included in this study. The articles were divided into groups of treatment. In studies where patients were treated with systemic chemotherapy with or without anti-angiogenic drugs, four out of the seven studies found a significant decrease in permeability after treatment. Four out of five studies that measured blood flow post anti-angiogenic treatments found that blood flow was significantly decreased. DCE-CT may be a useful tool in assessing treatment response in patients with lung cancer. It seems that particularly permeability and blood flow are important perfusion values for predicting treatment outcome. However, the heterogeneity in scan protocols, scan parameters, and time between scans makes it difficult to compare the included studies.
Introduction
Lung cancer is the leading cause of cancer death in males and the second leading cause in females next to breast cancer [1] . Despite improvements in treatment, the five-year survival rate is still low at 18% in patients with lung cancer in the USA [2] . Chances of survival are highly dependent on early detection, but most symptoms do not appear until the disease is already at an advanced stage [3] . Thus, early detection and early assessment of treatment response is essential.
Chemotherapy combined with anti-angiogenic drugs has shown great potential for patients with advanced lung cancer [4, 5] . With the introduction of anti-angiogenic drugs, Response Evaluation Criteria in Solid Tumors (RECIST) may be inadequate to evaluate tumor response to treatment. RECIST classifies patients as responders or non-responders primarily due to changes in tumor size [6] . However, anti-angiogenic drugs inhibit tumor growth and progression rather than causing tumor regression. Therefore, new functional imaging techniques aimed at measuring changes in vascular patterns are required [7] .
The articles were divided into groups according to treatment as shown in Tables 1 and 2 . Of the 16 articles, seven used systemic chemotherapy alone or combined with anti-angiogenic drugs as treatment (Table 1) . In three studies, the patients were treated with radiotherapy, in one study patients were treated with chemotherapy, radiotherapy, or concurrent chemoradiotherapy. Treatments used in the last five articles were thermotherapy, intra-arterial chemotherapy, or target therapy, such as recombinant human endostatin (RHES), anti-epidermal growth factor receptor (EGFR), or anti-angiogenic drugs. These were categorized as others ( Table 2 ). The articles were divided into groups according to treatment as shown in Tables 1 and 2 . Of the 16 articles, seven used systemic chemotherapy alone or combined with anti-angiogenic drugs as treatment (Table 1) . In three studies, the patients were treated with radiotherapy, in one study patients were treated with chemotherapy, radiotherapy, or concurrent chemoradiotherapy. Treatments used in the last five articles were thermotherapy, intra-arterial chemotherapy, or target therapy, such as recombinant human endostatin (RHES), anti-epidermal growth factor receptor (EGFR), or anti-angiogenic drugs. These were categorized as others (Table 2) .
Most articles used RECIST as gold standard, but four articles had no available gold standard [15] [16] [17] [18] . Lind et al. referred to RECIST and Crabb, which is a tumor evaluation tool for cavitating lesions that subtracts the longest diameter of cavitation from the longest diameter of the lesion [19] .
Jiang et al. performed a randomized clinical trial [18] , while the 15 others were prospective studies. Jiang et al. had no baseline DCE-CT scan [18] , while all others performed at least one baseline DCE-CT scan to compare to scans post-treatment. Two studies by Ng et al. had two baseline DCE-CT scans [16, 17] .
In 12 studies, patients with non-small cell lung cancer (NSCLC) were included. Fraioli et al. included patients specifically with adenocarcinoma [20] . Sudarski et al. included patients with NSCLC and patients with small cell lung cancer (SCLC) [21] , Zhao et al. included patients with all types of lung cancer [22] , and Hegenscheid et al. included patients with pulmonary metastases [23] .
The CT scanners used in 15 articles varied from 8 to 320 slices. Six of these scanners were less than 64-slice scanners. In one study by Zhao et al. the model of scanner was not available [22] . 4 (p = 0.032) and CBR 5 (p = 0.0045).
Significantly difference in decrease of BF* (p = 0.034), BV* (p = 0.019), and PS* (p = 0.006) between group 1 and 2. Significantly difference in increase of MTT* (p = 0.0124) between the two groups.
The study suggests that an anti-angiogenic drug administrated four days before chemotherapy is better than chemotherapy combined with the anti-angiogenic from the first day. DCE-CT* could be a reasonable method for evaluating patients after treatment. To assess the in vivo acute vascular effects of fractionated radiotherapy for human NSCLC* using DCE-CT*. BF* BV* MTT* PS* RECIST* BF* at baseline were significantly higher (p = 0.023) in responders than non-responders. The follow-up patients were divided into two groups due to changes in PS* after treatment.
The group with decrease of PS* (n = 11) had a significant longer median PFS* (p < 0.001) and median OS* (p = 0.004) than the group with increase in PS* (n = 11).
NSCLC* with high perfusion is relatively sensitive to chemo-radiation therapy. DCE-CT* is useful in predicting early tumor response and the prognosis of NSCLC* after treatment. BV* in the research group were significant higher (p = 0.000) on day 5, than in the control group. PS* in the research group were significant lower (p = 0.001) on day 5, than in the control group.
The study confirms that there is a RHES* "time window" of vascular normalization in human body. 
Systemic Chemotherapy with or without Anti-Angiogenic Drug (Seven Studies)
Data presented in Table 1 vary in time interval from treatment start to the first follow-up DCE-CT scan, with time between these two events ranging from 21 to 90 days.
The DCE-CT scans were executed with different scan protocols and scanners. Patients received between 40 mL and 108 mL of intravenous non-ionic contrast media-none of which were weight dependent-and with different flow rates and intervals. In four studies, tube voltage ranged from 80 kVp to 120 kVp and tube current ranged from 36 mAs to 120 mAs [20] [21] [22] 24] . In three studies, scan parameters were not available [25] [26] [27] .
In four of the seven studies there was a significant decrease in permeability between baseline DCE-CT scans and DCE-CT scans performed after treatment start [20, 21, 24, 25] . Zhang et al. showed a decrease in permeability, but did not test for significance between baseline scan and follow-up, instead testing for a significant difference in decreased permeability between two different treatment methods [27] . Two studies found no significant change in permeability [22, 26] .
In two studies, blood flow decreased significantly after treatment [20, 24] , three studies showed no significant changes [21, 22, 26] , and Tacelli et al. did not measure blood flow [25] . Zhang et al. found a decrease in blood flow but tested for significance between two different treatment methods [27] .
Blood volume decreased significantly after treatment in four studies. Of these four studies, a study by Fraioli et al. showed significant decrease for all included patients [20] , a study by Tacelli et al. showed a significantly greater decrease in responders than non-responders in patients treated with chemotherapy and anti-angiogenic drug [25] , a study by Wang et al. showed a significant decrease in responders only [26] , and one study by Zhao et al. showed a significant decrease of blood volume in responders and a significant increase of blood volume in non-responders [22] . Fraioli et al. showed a significant difference in blood volume between subtypes of NSCLC [24] , while Sudarski et al. showed a significant difference in blood volume between NSCLC and SCLC [21] . Zhang et al. found a decrease in blood volume, but tested for a significant difference in decreased blood volume between two different treatment methods instead [27] . Wang et al. also found that a difference in blood volume was a significant indicator of progression-free survival, and showed that blood volume and progression-free survival were significantly and inversely correlated [26] .
Three studies divided patients into treatment groups of chemotherapy combined with anti-angiogenic drugs or chemotherapy alone [24] [25] [26] . Tacelli et al. found a significant decrease in permeability and blood volume in the group of patients who were treated with combined chemotherapy and anti-angiogenic drug, and no significant changes in the group treated with chemotherapy alone [25] . Wang et al. found significantly longer progression-free survival in responders treated with combined chemotherapy and anti-angiogenic drugs than responders treated with chemotherapy alone [26] . The same study showed a significant decrease in blood volume after treatment in responders in the combined arm (chemotherapy combined with antiangiogenic drugs), but no significant changes in the single arm (chemotherapy). Furthermore, a significant inverse correlation between blood volume and progression-free survival was found only in the combined arm. Fraioli et al. did not test the different treatments against each other [24] .
Radiotherapy (3 Studies)
All three articles concerning radiotherapy were written by the same authors, Ng et al., and were performed with uniform scan protocols. The patients all received non-ionic contrast media with the same intervals, flowrate, and amount (108 mL). In two studies, the tube current was 120 mAs [15, 16] and in one study a tube current of 60 mAs was used [17] . All three studies scanned at 80 kVp and had first follow-up scans one week after baseline scans. All patients included in the three studies were treated with palliative fractionated radiotherapy.
One study showed that permeability increased significantly in tumor rim after a second fraction of radiotherapy [16] . Another study showed that permeability increased significantly in six out of eight patients after radiotherapy, and the changes were greater at the rim of tumor, as opposed to the center [15] . One study did not measure permeability [17] .
All studies measured blood volume. Two studies showed a significant increase after treatment when whole tumor was evaluated [16, 17] . One study showed a decrease in blood volume, after treatment of the anti-vascular drug (CA4P) [15] .
Patients in one study were given CA4P one week after second fraction radiotherapy [15] . This study showed a significant decrease in blood volume 4-72 h after patients received the anti-vascular drug, and significantly greater decrease of the tumor rim than center. The increase of permeability after radiotherapy, before CA4P, correlated with the decrease of blood volume in tumor rim after CA4P.
Chemoradiotherapy (One Study)
Wang et al. did not distinguish between patients treated with chemotherapy, radiotherapy, or concurrent chemoradiotherapy [28] . Based on RECIST, responders had a significantly higher blood flow than non-responders prior to treatment. Patients who underwent a second DCE-CT scan after treatment were divided into two groups according to changes of permeability. The group with a decrease in permeability had a significantly longer median progression-free survival period and longer median overall survival period than the group with an increase in permeability.
Others (Five Studies)
None of the patients in this group were treated with systemic chemotherapy or radiotherapy. Three studies used target therapy of RHES, anti-EGFR, or anti-angiogenic drugs. Hegenschied et al. used laser-induced thermotherapy [23] and Li et al. used intra-arterial infused chemotherapy [29] .
Jiang et al. performed no baseline scan [18] . First follow-up scans varied from one day to three weeks after treatment. Li et al. only performed baseline scans [29] . Scans were executed with tube voltage ranging from 80 to 120 kVp and tube current of 50-115 mAs. In four studies, patients received between 40 and 50 mL non-ionic contrast media, while Qiao et al. dosed contrast media according to weight [30] .
Li et al. used dual input to distinguish between bronchial and pulmonary blood flow [29] . The remaining four articles placed a single region-of-interest (ROI) in aorta and used a single input to extract perfusion data.
Hegenschied et al. showed a significant increase in mean transit time and a significant decrease in blood flow, blood volume, and permeability one day after treatment [23] .
The three studies on target therapy treatment all showed an effect on blood flow. For patients treated with anti-angiogenic drugs, Jiang et al. showed a significant increase from day 1 to day 5, and then a significant decrease from day 5 to day 10 [18] . Lind et al. showed a significant decrease in blood flow 3-6 weeks after treatment in patients treated with anti-angiogenic drugs and anti-EGFR drugs [19] . They also found significantly lower blood flow in responders than in non-responders 3-6 weeks after treatment. Qiao et al. also found a significant decrease in blood flow in responders treated with anti-EGFR [30] . The same study showed that patients with a decrease in blood flow had a significantly longer median progression-free survival.
Li et al. measured bronchial flow, and showed that responders had a significantly higher bronchial flow than non-responders before treatment [29] . They also showed that bronchial flow is a significant prognostic factor for progression-free survival and overall survival.
Bias and Applicability
The studies included in this analysis were evaluated on risk of bias and applicability by two authors (L.S.S. and C.A.L.) according to QUADAS-2. Results of the QUADAS-2 test are shown in Table 3 . Fraioli et al. 2011 [20] Li et al. measured bronchial flow, and showed that responders had a significantly higher bronchial flow than non-responders before treatment [29] . They also showed that bronchial flow is a significant prognostic factor for progression-free survival and overall survival.
The studies included in this analysis were evaluated on risk of bias and applicability by two authors (L.S.S. and C.A.L.) according to QUADAS-2. Results of the QUADAS-2 test are shown in Table 3 . 
Discussion
Currently, there is no consensus on methods of measurements of perfusion using DCE-CT. The heterogeneity in setup and scan parameters makes it difficult to compare the studies presented in this paper. In studies measuring permeability before and after chemotherapy, four of seven showed a significant decrease in permeability after treatment [20] [21] [22] [24] [25] [26] [27] . Only two studies [15, 16] assessed changes in permeability after radiotherapy and both found an increase, however this finding would not necessarily reflect treatment response, but rather vessel damage and inflammation caused by the radiotherapy [31] . This systematic review indicates that cancer treatments, except radiotherapy, have an effect on permeability, resulting in its decrease. Tumors are often hyperpermeable, due to high density dysplastic vessels with abnormalities in vessel wall structure and large pores [32] . Hence, a decrease in permeability would suggest a normalization of the blood vessels in the tumor indicating treatment response. Permeability seems to be a promising perfusion value to estimate early treatment response.
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with anti-EGFR [30] . The same study showed that patients with a decrease in blood flow had a significantly longer median progression-free survival. Li et al. measured bronchial flow, and showed that responders had a significantly higher bronchial flow than non-responders before treatment [29] . They also showed that bronchial flow is a significant prognostic factor for progression-free survival and overall survival.
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Currently, there is no consensus on methods of measurements of perfusion using DCE-CT. The heterogeneity in setup and scan parameters makes it difficult to compare the studies presented in this paper. In studies measuring permeability before and after chemotherapy, four of seven showed a significant decrease in permeability after treatment [20] [21] [22] [24] [25] [26] [27] . Only two studies [15, 16] assessed changes in permeability after radiotherapy and both found an increase, however this finding would not necessarily reflect treatment response, but rather vessel damage and inflammation caused by the radiotherapy [31] . This systematic review indicates that cancer treatments, except radiotherapy, have an effect on permeability, resulting in its decrease. Tumors are often hyperpermeable, due to high density dysplastic vessels with abnormalities in vessel wall structure and large pores [32] . Hence, a decrease in permeability would suggest a normalization of the blood vessels in the tumor indicating treatment response. Permeability seems to be a promising perfusion value to estimate early treatment response. with anti-EGFR [30] . The same study showed that patients with a decrease in blood flow had a significantly longer median progression-free survival. Li et al. measured bronchial flow, and showed that responders had a significantly higher bronchial flow than non-responders before treatment [29] . They also showed that bronchial flow is a significant prognostic factor for progression-free survival and overall survival.
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Currently, there is no consensus on methods of measurements of perfusion using DCE-CT. The heterogeneity in setup and scan parameters makes it difficult to compare the studies presented in this paper. In studies measuring permeability before and after chemotherapy, four of seven showed a significant decrease in permeability after treatment [20] [21] [22] [24] [25] [26] [27] . Only two studies [15, 16] assessed changes in permeability after radiotherapy and both found an increase, however this finding would not necessarily reflect treatment response, but rather vessel damage and inflammation caused by the radiotherapy [31] . This systematic review indicates that cancer treatments, except radiotherapy, have an effect on permeability, resulting in its decrease. Tumors are often hyperpermeable, due to high density dysplastic vessels with abnormalities in vessel wall structure and large pores [32] . Hence, a decrease in permeability would suggest a normalization of the blood vessels in the tumor indicating treatment response. Permeability seems to be a promising perfusion value to estimate early treatment response. [29] . They also showed that bronchial flow is a significant prognostic factor for progression-free survival and overall survival.
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Unclear Risk.
Studies where patients were treated with anti-angiogenic drugs generally showed decrease in blood flow. Of the five studies that measured blood flow in patients who were treated with anti-angiogenic drugs, four showed a significant decrease in blood flow [19, 20, 24, 26, 27] . Because of tumor heterogeneity, blood flow is more complex and can vary considerably within a tumor. In parts of tumor with angiogenesis and where growth is active, such as the periphery of tumor, blood flow increases. However, in regions with high interstitial pressure, the capillaries will be compressed causing blood flow to decrease. This often results in areas of tissue hypoxia and necrosis [33] .
Four out of five studies that assessed the correlation between DCE-CT values and progression-free survival found that a decrease in permeability [28] or blood flow [19, 29, 30] corresponded to longer progression-free survival. Yao et al. found similar results for blood flow in patients with advanced carcinoid tumor treated with anti-angiogenic drugs [34] . Bisdas et al. found blood flow to be a predicator of progression-free survival in patients with oropharynx squamous cell carcinoma [35] . Both studies however were small and included 44 and 19 patients, respectively. Hence, further investigation is needed to draw any conclusions between blood flow and survival outcome.
Only one of the included studies was a randomized control trial [18] ; the remaining were prospective studies, which affect the level of evidence. In 12 of the 16 included studies, the reference standard was subject to high risk of bias and concerns of applicability. All but four studies used RECIST as a reference standard, and as there are concerns as to whether this tool for evaluating treatment response is the most accurate, especially in patients treated with anti-angiogenic drugs, the studies were disposed to high risk of bias.
Different vendors use different models to calculate perfusion values. Depending on which scanner is available, the kinetic model is predefined and they each have their pros and cons. The most widely used kinetic models are deconvolution and compartmental [12, 36] . The compartmental method is calculated from the maximum slope of attenuation either as a single compartment or double-compartment. Single compartment analyses consider the intravascular and the extravascular spaces as a single compartment [36] . During the first pass of contrast media (45-60 s after injection), most contrast media remains in the intravascular space, allowing the assumption of single compartment [36] . The studies which made use of the single compartment method were able to determine blood flow within a short overall length of scan time (ě45 s), which is a great advantage, especially when assessing lung tumors which are prone to breathing artifacts. The disadvantage is that this method is very sensitive to image noise and not able to measure permeability, which seems to be an important indicator of treatment response. The double-compartment is, however, able to measure permeability. This is done based on Patlak analysis which was performed in the majority of included studies [15] [16] [17] 20, 22, 24, 25] . This makes the assumption that there is no backflux of contrast media from the interstitial space to the intravascular space. For this assumption to be acceptable several conditions have to be met, and even then it is only valid for the initial 2 min [32, 33] . The compartment models require a high flowrate of contrast media (>7 mL/s) and is very susceptible to noise, which is why scans are often executed with higher tube current [36] .
Two of the included studies used the deconvolution method [21, 23] . This method uses time-density curves to calculate impulse residue function [32] . The deconvolution method tolerates greater images' noise, which allows lower tube current and higher temporal resolution due to the higher number of images. This, however, makes the deconvolution method predisposed to motion artifacts [37] and patients are exposed to higher overall radiation dose [32] . Deconvolution method is appropriate for measuring lower levels of perfusion (<20 mL/min/100 mL), which is beneficial in evaluation of treatment response [36] .
Very little data are available on direct comparison of these analysis methods, but preliminary investigations by Griffiths et al. have shown good correlation between the two methods in lung and spleen lesions, however the slope method showed consistently lower perfusion values. Hence, comparison of the two analytical methods should be done with caution [12] .
The study by Li et al. was the only study to use a dual input method to determine the perfusion values [29] . Lung tumors usually have a dual vascular supply, from both bronchial and pulmonary arteries. Studies have shown that the perfusion values differ from tumor location and size [38, 39] .
The clinical potential of DCE-CT is the possibility of early detection of perfusion changes corresponding to early response. The earliest response detected in the included studies were three weeks after start of chemotherapy [22, 25] which would be at a time where a decrease in size could be difficult to measure with RECIST criteria. According to RECIST, a frequency of tumor re-evaluation every 6-8 weeks is reasonable [6] . The potential to assess treatment response at an earlier time would enable the possibility to quickly change treatment for nonresponding patients, which would benefit patients and save money on unnecessary treatments.
Positron emission tomography (PET)/CT is an alternative functional imaging tool used to evaluate tumor response. While DCE-CT measures tumor vascularity, PET/CT can be used to measure tumor metabolism and tumor hypoxia using fludeoxyglucose (FDG)-PET and hypoxia PET. According to Harders et al. 18 F-FDG PET/CT is more validated and therefore preferred when it comes to diagnostic and staging of lung tumors. Therapy evaluation lacking in standardization for both modalities, but DCE-CT has shown great potential in patients treated with anti-angiogenic drugs in multiple smaller studies [40] . Since PET and DCE-CT seem to measure different aspects of tumors, few studies have investigated the correlation between these. However, Kim et al. found a significant positive correlation between parameters acquired from 18 F-FDG PET/CT and DCE-CT parameters in patients with liver metastasis [41] . In patients with NSCLC, Miles et al. found a significant correlation between metabolism and blood flow derived from 18 F-FDG PET/CT and DCE-CT, respectively, but only for tumors less than 4.5 cm 2 [42] . By contrast, van Elmpt et al. found no correlation between tumor metabolism and tumor vascularity on either population or subvolume level in patients diagnosed with NSCLC. Still, they did find a negative correlation between perfusion values, such as blood volume and blood flow, and hypoxia parameters [43] . Compared to PET/CT, DCE-CT has the advantage of being more available due to the widespread use of CT scanners. Furthermore, it is a faster and cheaper examination.
Another functional imaging tool which is generally more applied than DCE-CT is DCE-MRI, possibly because radiation dose does not need to be taken into count. Except from the difference in modalities, the overall method of the DCE-MRI is similar to that of DCE-CT, with some major differences. The contrast agent used in DCE-MRI is gadolinium and the most commonly used parameters are area under the contrast-agent-concentration time curve at 60 s (IAUC 60 ) and volume transfer contrast (K trans ). DCE-MRI is widely used in drug development, especially in development of vascular-targeting agents. O'Connor et al. demonstrates that even though DCE-MRI is able to monitor changes in vascularity, especially K trans , the lack of standardization causes the method to still be considered controversial. They point out that changes in DCE-MRI parameters do not guarantee survival benefits and hence changes in vascularity are necessary, but not sufficient, to evaluate efficiency of vascular-targeting agents [44] .
The main limitation of this review is the number and heterogeneity of the included studies. Some of the factors that make generalization uncertain are the differences in hardware, e.g., different vendors and scanner models, and the difference in scan protocols. Due to the fact that DCE-CTs are generally performed with highly various scan parameters, it is not possible to make a direct comparison of perfusions values, as they are affected by scan parameters such as tube current, tube voltage, scan duration, and contrast injection. Further complicating comparison is the fact that no consensus has yet been reached as to which analytic method is preferred to measure treatment response, and no standard of time is determined for when to perform follow-up scans to detect early changes in tumor. DCE-CT as a tool to evaluate treatment response is relatively new, and thus larger randomized studies are needed to establish standardizations.
Some of the limitations DCE-CT is restricted to is the number of detector rows of the scanner. Only three of the included studies used a CT scanner with more than 64 slices [21, 26, 29] . Hence, most studies were limited to a scan range of 4 cm or less, which disables whole tumor evaluation of larger tumors. DCE-CT of the lung is prone to different artifacts. Due to the high concentration of contrast media in the great vessels and the heart chambers, there are risks of beam-hardening, which should try to be avoided because it can affect perfusion values significantly [10] . Another artifact seen in DCE-CT of the lungs is respiratory motion. Most of the included studies worked with breath-hold or shallow breathing. Breath-hold is not appropriate for scans longer than 45 s as many patients tend to slowly exhale during the scan, causing motion artifacts [32] . Therefore, motion correction software is often applied [40] . Motion artifacts have a big influence on reproducibility. Lee et al. found that reproducibility improved with whole tumor coverage and motion correction [45] . Other studies have shown generally acceptable [46] to good reproducibility [47] of perfusion values in patients with colorectal and rectal cancer, respectively. Goh et al. found that reproducibility in colorectal cancer was superior to that of skeletal muscle [48] . Few studies have investigated reproducibility in DCE-CT in lung cancer, probably due to the risk of radiation. Ng et al. demonstrated variability in measurements of blood flow and permeability at best 11.6% and 30.2%. They concluded that reproducibility of perfusion values in lung tumors are very much affected by motion and duration of data acquisition [49] .
In conclusion, DCE-CT is a potential tool of evaluating tumor response in patients with lung cancer. Permeability and blood flow seem to be important perfusion values regarding assessment of early treatment response. However, the heterogeneity of scan protocols, scan parameters and time to
